secwatch.observer — SEC 8-K summary
======================================

Issuer:     Skye Bioscience, Inc. (SKYE)
CIK:        0001516551
Form:       8-K
Filed at:   2021-12-20T23:59:59+00:00
Accession:  0001516551-21-000031
Event type: leadership
Sentiment:  positive
Materiality: 0.50
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Skye Bioscience appoints Dr. Keith Ward to board, promotes Tu Diep to CDO
-------------------------------------------------------------------------

- Dr. Ward elected to board; receives $40K annual director fee, $1K committee pay, and options for 250K shares vesting monthly over one year.
- CEO Punit Dhillon granted 2,000,000 RSUs and 3,090,000 stock options at $0.058/share; Kaitlyn Arsenault granted 1,000,000 RSUs and 1,770,000 options.
- Tu Diep promoted from SVP of Development to Chief Development Officer, effective immediately.
- Options to Dhillon and Arsenault vest 25% at one year then monthly; fully vest on change of control; expire Dec 14, 2031.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1516551/000151655121000031/0001516551-21-000031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1516551/000151655121000031/skye-20211214.htm
  HTML page:      https://secwatch.observer/filing/0001516551-21-000031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer